Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
News|Videos|June 30, 2026
10 Experts Predict the Future of CTCL Treatment
Fact checked by: Kevin Kunzmann
At the 6th World Congress of Cutaneous Lymphoma, a group of world-leading CTCL expert consider what the field will abandon in the next decade.
Advertisement
Advertisement
Progression may feel slower in rare disease fields such as cutaneous T-cell lymphoma (CTCL) —the dearth of patients mean fewer data to inform clinical investigation, which means a more stagnant pipeline.
Related to this article
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.
Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.
Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.
A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.
Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.
Advertisement
Advertisement